Bevacizumab biosimilar - Allergan/Amgen

Drug Profile

Bevacizumab biosimilar - Allergan/Amgen

Alternative Names: ABP-215; Bevacizumab-awwb; Kyomarc; Mvasi

Latest Information Update: 08 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen; Watson Pharmaceuticals
  • Developer Allergan; Amgen
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Cervical cancer; Colorectal cancer; Glioblastoma; Non-small cell lung cancer; Renal cell carcinoma
  • Preregistration Breast cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer

Most Recent Events

  • 08 Dec 2017 Amgen and Allergan's bevacizumab biosimilar is not yet commercially available in USA (IV) (literature review).
  • 10 Nov 2017 Amgen withdraws its duplicate Marketing Authorisation Application for bevacizumab biosimilar (Kyomarc™) for Colon cancer, Breast cancer, Non-small cell lung cancer, Kidney cancer, Cervical cancer, Ovarian cancer, Fallopian tube cancer and Peritoneal cancer in European Union .
  • 10 Nov 2017 The Committee for Medicinal Products for Human Use (CHMP) recommends approval of bevacizumab biosimilar (Mvasi™) for Non-small cell lung cancer, Colorectal cancer, Breast cancer, Renal cell carcinoma, Peritoneal cancer, Fallopian tube cancer, Ovarian cancer, Cervical cancer in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top